Screener
Celldex Therapeutics CLDX Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $22K-97.0% | $15K-97.8% | $121K-89.7% | $0-100% | $730K-70.8% | ||
| $67.54M+24.6% | $73M+38.7% | $75.33M+60.5% | $62.93M+39.0% | $54.2M+36.6% | ||
| $13.1M+26.1% | $11.45M+5.8% | $11.94M+16.3% | $10.69M+6.3% | $10.39M+13.8% | ||
| $80.65M+24.9% | $84.45M+33.1% | $87.27M+52.6% | $73.62M+33.1% | $64.59M+32.3% | ||
| -$80.62M-26.3% | -$84.44M-34.6% | -$87.15M-55.6% | -$73.62M-41.2% | -$63.86M-37.9% | ||
| -366,468.2%-357,721pp | -562,900%-553,873pp | -72,027.3%-67,259pp | —— | -8,747.5%-6,893pp | ||
| -$73.5M-29.9% | -$78.69M-46.3% | -$81.32M-72.7% | -$67.04M-59.2% | -$56.6M-57.9% | ||
| -334,104.5%-326,351pp | -524,566.7%-516,826pp | -67,204.1%-63,196pp | —— | -7,753.4%-6,319pp | ||
| -$0.94-10.6% | -$1.18-45.7% | -$1.23-73.2% | -$1.01-57.8% | -$0.85-57.4% | ||
| -$79.72M-26.6% | -$83.58M-35.1% | -$86.34M-56.4% | -$72.79M-41.8% | -$62.98M-38.4% | ||
| -362,368.2%-353,740pp | -557,206.7%-548,304pp | -71,352.9%-66,654pp | —— | -8,627.9%-6,806pp | ||
| -$80.62M-26.3% | -$84.44M-34.6% | -$87.15M-55.6% | -$73.62M-41.2% | -$63.86M-37.9% |
FAQ
- What is Celldex Therapeutics's revenue?
- Celldex Therapeutics (CLDX) generated $158.0K in revenue over the trailing twelve months, down 97.3% year over year.
- Is Celldex Therapeutics profitable?
- Celldex Therapeutics is not currently profitable: it reported a net loss of $300.5M over the trailing twelve months, a -190220.9% net margin.
- What is Celldex Therapeutics's earnings per share?
- Celldex Therapeutics's diluted EPS over the trailing twelve months is $-4.36.
- Where does Celldex Therapeutics's income statement data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
